Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Plural ring hetero atoms in the bicyclo ring system

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514228800 - Hetero ring is six-membered and includes at least nitrogen and oxygen as ring hetero atoms (e.g., monocyclic 1,2- and 1,3-oxazines, etc.)

514231200 - Morpholines (i.e., fully hydrogenated 1,4- oxazines)

514231500 - Additional hetero ring attached directly or indirectly to the morpholine ring by nonionic bonding

514232800 - Polycyclo ring system having the additional hetero ring as one of the cyclos

514233500 - Bicyclo ring system having the additional hetero ring as one of the cyclos

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514234500 Plural ring nitrogens in the bicyclo ring system 333
514234200 Three or more ring hetero atoms in the bicyclo ring system 313
Entries
DocumentTitleDate
20090118272BENZOTHIAZOLE AND AZABENZOTHIAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS - A compound of Formula (I)05-07-2009
20120245167ARTHROPOD PEST CONTROL METHOD AND COMPOSITION - Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein A09-27-2012
20130079340Benzothiazoles Having Histamine H3 Receptor Activity - Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings, having histamine H3 antagonistic activity can be used in pharmaceutical compositions.03-28-2013
20130040948NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS - The present invention is concerned with novel dual modulators of the 5-HT02-14-2013
20100324039Substituted Indolealkanoic Acids - Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.12-23-2010
20120165327SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS - The present invention is directed to a compound of Formula (I):06-28-2012
20090042877Bicyclic Heteroaromatic Derivatives - Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(R02-12-2009
20100137301Substituted Indolealkanoic Acids - Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.06-03-2010
20100075959BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS - The present invention relates to substituted benzothiazole derivatives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.03-25-2010
20130165438PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS - The present invention provides a piperidine compound represented by Formula (I)06-27-2013
20120270869PYRIDYL DERIVATIVES AS CFTR MODULATORS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.10-25-2012
200902475163- (BENZO [D] [1,3] DIOXOL-5-YLMETHYL) -4- (THIO) OXO-2- (THIO) OXO-AZOLIDIN-5-YLIDENE DERIVATIVES AS ANTIBACTERIAL AGENTS - The present invention concerns novel azolidine compounds of Formula (I) wherein X denotes S, NH, CH2 or O, Y and W denotes each independently S or O, Q denotes CH or N, n and m are an integer from 0 to 2, and R1 and R2 denote independently from each other hydrogen, optionally substituted aryl, optionally substituted heterocyclyl, or an optionally substituted (C1-10) aliphatic group, R3 denotes hydrogen, lower alkyl, halogen, lower alkoxy, nitro, and R4 and R5 denote independently from each other hydrogen, halogen or alkyl, with the proviso that if one of R1 and R2 is hydrogen then the respective other one of R1 and R2 does not denote substituted or unsubstituted 2-furyland their salts, that are useful as pharmaceutical agents, e.g. as antibacterial agents, and to pharmaceutical compositions comprising such compounds.10-01-2009
20110144102CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY - This invention relates generally to the field of medicine and, more specifically, to methods for treating epithelial injury, in particular, due to ischemia, hypoxia, trauma, chemolytics or radiation exposure.06-16-2011
20100222341PIPERIDINE AND PIPERAZINE DERIVATIVES - Compounds of the formula (I), in which R09-02-2010
200903184395-FUROPYRIDINONE SUBSTITUTED INDAZOLES - Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.12-24-2009
20090318438Heterocyclic compounds and their use as anticancer agents - The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture.12-24-2009
20110269756BENZOTHIAZOLONE DERIVATIVES - Compounds of the formula I, in which R11-03-2011
20100099671GLUCOKINASE ACTIVATOR - A compound, or a pharmaceutically acceptable salt thereof, represented by the formula (1),04-22-2010
20090258873Novel tetrahydropyridothiophenes - Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.10-15-2009
20080312226Amide Compound - There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I12-18-2008
20080280898Spiro-piperidine derivatives - The present invention is concerned with novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases.11-13-2008
20100048558THIENOPYRIDINES - The invention relates to novel thienopyridine derivatives of formula (I), wherein R1, R2, R3, R4 and Y have the meaning cited in claim 02-25-2010
20080306061Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor - The present invention concerns substituted aminophenylsulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds and derivatives with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.12-11-2008
20080306060Fused Thiazole Derivatives as Kinase Inhibitors - A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.12-11-2008
20080306062MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.12-11-2008
20100324038TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER - The invention relates to compounds of formula I, wherein Ra is —C(O)OR1, in which R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and either Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl or naphthyl, or Q is optionally substituted by Rca and/or Rcb, and is Har, or Q is optionally substituted by Rda and/or Rdb, and is Het, or Q is optionally substituted by Rea and/or Reb, and is 3-7C-cycloalkyl, which are useful for the therapy of hyperproliferative diseases, in particular human cancer.12-23-2010
20090054430Inhibitors of Protein Kinases - Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.02-26-2009
20080318946Di-amino-substituted heterocyclic compounds and methods of use - The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various fibrotic and mast cell related diseases such as mastocytosis. The compounds have a general Formula I12-25-2008
20080234260Cysteine Protease inhibitors - A compound of the formula II09-25-2008
20080261971Novel Heterocyclic Nf-Kb Inhibitors - The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, (I) wherein R10-23-2008
20090105245METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR - The present invention provides methods for inhibiting increased vascular permeability and/or pathologic ocular angiogenesis via administration of a combination of one or more molecules that potently inhibit select receptor tyrosine kinases (RTKs) or vascular endothelial growth factor (VEGF) and one or more anti-inflammatory agents.04-23-2009
20100160312Substituted Pyridone Compounds and Methods of Use - The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I06-24-2010
20090048248Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists - The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.02-19-2009
20080214539Benzisoxazole Piperidine Compounds and Methods of Use Thereof - The invention includes benzisoxazole piperidine compositions and methods of using them for modulating sleep.09-04-2008
20110059960METHOD OF TREATING INHERITED SEVERE NEUTROPENIA - The invention is directed to a method of treating severe neutropenia, and in particular, cyclic neutropenia (CN) or severe congenital neutropenia (SCN), in a patient in need of such treatment comprising: administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.03-10-2011
20110112089Cysteine Protease Inhibitors - A compound of the formula II05-12-2011
20090105244THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR - The present invention relates to selective allosteric potentiators of the Formula (I):04-23-2009
20100298316Benzothiazoles Having Histamine H3 Receptor Activity - Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings,! of the general formula (1): having histamine H3 antagonistic activity can be used in pharmaceutical compositions.11-25-2010
20090036443Thienopyrroles as antiviral agents - The present invention relates to thienopyrrole compounds of formula (I); wherein A, B, Y, Ar, n, Z and X02-05-2009
20110034457Pyridothiophene Compounds - The use of compounds of formula (I) in therapy, particularly for the treatment of a disorder mediated by excessive or inappropriate HSP90 activity formula (I), wherein R02-10-2011
20110039843HARMFUL ARTHROPOD CONTROL COMPOSITION, AND FUSED HETEROCYCLIC COMPOUND - Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein A02-17-2011
20090209534NOVEL COMPOUNDS AND USE OF TETRAHYDROPYRIDOPYRIDOTHIOPHENES - The use of tetrahydropyridothiophenes of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, is novel for treating hyperproliferative diseases and/or disorders responsive to the induction of apoptosis.08-20-2009
20110144103PYRROLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted pyrrole compounds and compositions comprising substituted pyrrole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted pyrrole compound of the invention, or a pharmaceutical composition comprising such a compound.06-16-2011
20110098292New Compounds Useful for Treating CNS Disorders - The present invention provides new compounds of formula (I) as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.04-28-2011
20090312318THERAPEUTIC COMPOUNDS AND METHODS - The present invention provides compounds of Formula (I): wherein A, X, Q, R12-17-2009
20100056513STEREOSPECIFICALLY SUBSTITUTED BENZO[1,3]DIOXOLYL DERIVATIVES - The present invention relates to compounds of formula (I)03-04-2010
20110098293Inhibitors of Protein Tyrosine Kinase Activity - This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.04-28-2011
20110105497COMPOUNDS AND METHODS FOR TREATMENT OF CANCER - Compounds for treating, preventing or managing cancer are disclosed. Also provided are methods for using the compounds in treatment of various cancers. Also provided are methods of treatment using the compounds together with another chemotherapy, radiation therapy, hormonal therapy, biological therapy, or immunotherapy. Pharmaceutical compositions suitable for use in the methods are also disclosed.05-05-2011
20120202808NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE - A compound of formula (1):08-09-2012
20110212959Cyanoisoquinoline Compounds and Methods of Use Thereof - The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:09-01-2011
20090029986N-AROYL CYCLIC AMINES - Disclosed are N-aroyl cyclic amine derivatives having the formula:01-29-2009
20100331326Inhibitors of CYP 17 - The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof,12-30-2010
20110257175Selected Inhibitors of Protein Tyrosine Kinase Activity - The invention provides new compounds and compositions thereof. The invention also provides methods for treating ophthalmic diseases, disorders and conditions.10-20-2011
20100298317METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES - A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.11-25-2010
20110136804Nicotinic Acetylcholine Receptor Ligands 101 - Nicotinic acetylcholine receptor ligands of Formula I06-09-2011
20110178079GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS - Novel guanidine compounds having the formula07-21-2011
20090069317Insecticidal Methods Using 3-Amino-1,2-Benzisothiazole Derivatives - The invention relates to insecticidal methods using 3-amino-1,2-benzoisothiazole compounds of the formula (I) wherein the variables n and R03-12-2009
20090082345BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS - The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment.03-26-2009
20100099672METHODS FOR TREATING HEPATITIS C - In accordance with the present invention, compounds that can inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the invention, compounds useful in the treatment or prevention of HCV infection are provided.04-22-2010
20120040980QUINAZOLINONE COMPOUNDS - The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula (I).02-16-2012
201100711474-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES - Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon, lung and prostate. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer using these compounds.03-24-2011
20090029987Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices - The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.01-29-2009
20110166134Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease - A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.07-07-2011
20120108586ARTHROPOD PEST CONTROL METHOD AND COMPOSITION - Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein A05-03-2012
20120108585BENZOXAZOLES, BENZTHIAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.05-03-2012
201001521822,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors - Disclosed are pyrimidine derivatives of formula06-17-2010
20110105496Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds - This invention relates generally to methods for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions.05-05-2011
20120316162PIPERIDINE AND PIPERAZINE DERIVATIVES - Compounds of the formula (I), in which R12-13-2012
20090131428BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS - The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer treatment.05-21-2009
20120252803COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS - The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and a pyrethroid compound; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and a pyrethroid compound to the arthropod pests or a locus where the arthropod pests inhabit; and so on.10-04-2012
20120252804COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS - The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and pyriproxyfen; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and pyriproxyfen to the arthropod pests or a locus where the arthropod pests inhabit; and so on.10-04-2012
20120252805NOVEL COMPOUNDS - The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase II enzyme.10-04-2012
20120178752RHO KINASE INHIBITORS - The present invention relates to compounds of formula (I):07-12-2012
20100022530TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN - Compounds of the formula (I) in which A01-28-2010
20100016304GLUCOKINASE ACTIVATOR - A compound represented by the following formula (1):01-21-2010
20120220583SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase activity and for the treatment of diseases, including Alzheimer's disease (AD) and related CNS conditions, mediated thereby. In one embodiment, the compounds have a general Formula I08-30-2012
20120225868NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS - The present invention is concerned with novel dual modulators of the 5-HT09-06-2012
20120258967PI3 KINASE INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same.10-11-2012
200900364445-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor - The present invention relates to a fused ring compound represented by the following formula [I]02-05-2009
20120264750COMPOSITION AND METHOD FOR CONTROLLING ARTHROPOD PESTS - The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and a diamide compound; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and a diamide compound to the arthropod pests or a locus where the arthropod pests inhabit; and so on.10-18-2012
20100179141NOVEL JNK INHIBITORS - Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR07-15-2010
20120270868RHO KINASE INHIBITORS - The present invention relates to compounds of formula (I):10-25-2012
20120322798Modulators of ATP-Binding Cassette Transporters - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.12-20-2012
201002343695-CYANOTHIENOPYRIDINES FOR THE TREATMENT OF TUMOURS - Novel 5-cyanothienopyridines of the formula (I), in which R09-16-2010
201102511931,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES - Novel classes of 1,2-benzisothiazolinone and isoindolinone compounds and compositions are disclosed. These compounds and compositions are useful in treating, preventing, and/or ameliorating viral, yeast, and fungal infections such as, for example, Hepatitis C Virus, Flavivirus infections, 10-13-2011
20100216787THIAZOLE DERIVATIVE - A thiazolylimidazole derivative represented by the formula08-26-2010
20100168097Non-Nucleoside Reverse Transcriptase Inhibitors - Compounds of Formula I: Formula (I); are HIV reverse transcriptase inhibitors, wherein R07-01-2010
20100130490CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE - Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.05-27-2010
20130178471MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.07-11-2013
20080214540Substituted indolealkanoic acids - Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.09-04-2008
20110224204DI-SUBSTITUTED PHENYL COMPOUNDS - Di-substituted phenyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. The disclosure also relates to methods for treating neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.09-15-2011
201003176584,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses - A subject of the present invention is 4,7-dioxobenzothiazole-2-carboxamide derivatives, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.12-16-2010
20110312958MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.12-22-2011

Patent applications in class Plural ring hetero atoms in the bicyclo ring system

Patent applications in all subclasses Plural ring hetero atoms in the bicyclo ring system